These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 29200419)
21. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Shapiro RM; Kim DDH Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033 [TBL] [Abstract][Full Text] [Related]
22. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335 [TBL] [Abstract][Full Text] [Related]
23. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them. Li SQ; Chen M; Huang XY; Wang H; Chang YJ Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882 [TBL] [Abstract][Full Text] [Related]
24. Is it time to routinely incorporate MRD into practice? Ravandi F Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755 [TBL] [Abstract][Full Text] [Related]
25. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia]. Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363 [TBL] [Abstract][Full Text] [Related]
26. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957 [TBL] [Abstract][Full Text] [Related]
27. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia. Blackmon AL; Hourigan CS Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547 [TBL] [Abstract][Full Text] [Related]
28. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765 [TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients. Sun Y; Zhu G; Zhong H Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613 [TBL] [Abstract][Full Text] [Related]
31. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Al-Mawali A; Gillis D; Lewis I Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068 [TBL] [Abstract][Full Text] [Related]
32. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Köhnke T; Sauter D; Ringel K; Hoster E; Laubender RP; Hubmann M; Bohlander SK; Kakadia PM; Schneider S; Dufour A; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Spiekermann K; Subklewe M Leukemia; 2015 Feb; 29(2):377-86. PubMed ID: 24912430 [TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Kayser S; Walter RB; Stock W; Schlenk RF Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952 [TBL] [Abstract][Full Text] [Related]
34. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia. Roug AS; Ommen HB Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904 [TBL] [Abstract][Full Text] [Related]
35. Monitoring of minimal residual disease in acute myeloid leukemia. Kern W; Haferlach C; Haferlach T; Schnittger S Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811 [TBL] [Abstract][Full Text] [Related]
37. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression]. Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135 [TBL] [Abstract][Full Text] [Related]
38. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. Tomlinson B; Lazarus HM Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434 [TBL] [Abstract][Full Text] [Related]